Neurology 2017-11-14T15:19:28+00:00

Our Work in Neurology

Specialized patient populations that require unique or complex therapies will continue to make neurology the target for dynamic research and commercial markets. With a specific focus on the multiple sclerosis (MS) market in the US and the EU, Spherix is shedding light on the key dynamic issues in this fast moving category as the increased risk tolerance and the expanding number of therapies evolves the treatment strategies for all forms of MS.

VIEW REPORTS OFFERED IN THIS AREA

Diseases Covered

Multiple Sclerosis, Rare Neurological Diseases

Board of Advisors

Coming soon.

Advocacy Groups

The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with MS and those who are close to them.

RECENT PUBLICATIONS

FDA Approval of Mylan’s Glatiramer Acetate Will Turn the Payer Pressure On for Teva’s Copaxone and Sandoz’s Glatopa – October 4, 2017
>VIEW ARTICLE

First-in-Class PPMS Indication Fueling Much of the Adoption of Genentech’s Ocrevus, but Insurance Coverage Issues Could be a Looming Stumbling Block – September 19, 2017
>VIEW ARTICLE

Early Uptake of Roche/Genentech’s Ocrevus Off to Stellar Start, According to Latest Quarterly Update from Spherix Global Insights – July 19, 2017
>VIEW ARTICLE

UPCOMING CONFERENCES

2017 ECTRIMS Meeting
>LEARN MORE

2018 ACTRIMS Meeting
>LEARN MORE

HELPFUL LINKS